Categories | Inventors

pLXSN human KIT D816F retrovirally transduced BaF3 cells


OHSU # 1658-C

Technology Overview:

Technology Overview
Neomycin resistant and growth factor independent. This cell line expresses high levels of activated KIT. In addition to the engineered D816F mutation, the cells also acquired the following mutations due to retrovirus recombination events: I571M and M903I. These secondary events do not appear to alter the kinase properties of KIT or alter the pattern of KIT D816F sensitivity/resistance to kinase inhibitors.



For more information, contact:

Trina Voss
Technology Development Manager

(terms)  $0.00
(terms)  $10000.00